KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Change in Intangibles: 2013-2021

Historic Change in Intangibles for Supernus Pharmaceuticals (SUPN) over the last 5 years, with Mar 2021 value amounting to $453,000.

  • Supernus Pharmaceuticals' Change in Intangibles was N/A to $453,000 in Q1 2021 from the same period last year, while for Mar 2021 it was $1.9 million, marking a year-over-year change of. This contributed to the annual value of $1.3 million for FY2019, which is 66.75% up from last year.
  • Per Supernus Pharmaceuticals' latest filing, its Change in Intangibles stood at $453,000 for Q1 2021, which was up 287.18% from $117,000 recorded in Q3 2020.
  • Over the past 5 years, Supernus Pharmaceuticals' Change in Intangibles peaked at $5.8 million during Q2 2017, and registered a low of $1,000 during Q1 2019.
  • For the 3-year period, Supernus Pharmaceuticals' Change in Intangibles averaged around $388,600, with its median value being $117,000 (2020).
  • Examining YoY changes over the last 5 years, Supernus Pharmaceuticals' Change in Intangibles showed a top increase of 936.92% in 2019 and a maximum decrease of 99.71% in 2019.
  • Supernus Pharmaceuticals' Change in Intangibles (Quarterly) stood at $1.0 million in 2017, then tumbled by 87.30% to $130,000 in 2018, then soared by 936.92% to $1.3 million in 2019, then reached $117,000 in 2020, then reached $453,000 in 2021.
  • Its Change in Intangibles stands at $453,000 for Q1 2021, versus $117,000 for Q3 2020 and $24,000 for Q2 2020.